Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, ... In recent years, blockbuster glucagon-like peptide 1 receptor agonist (GLP-1RA) ...

IBIO-600 is the product of an existing relationship between iBio and Boston-based AstralBio signed in March 2024 that saw the two biotechs advance a joint myostatin program for cardiometabolic ...

Drug companies are also testing whether blocking myostatin can help preserve muscle in people using GLP-1 receptor weight loss drugs, such as Ozempic, which can lead to both fat and muscle loss.

"Regulatory precedent for myostatin-based therapies in combination with GLP-1 receptor agonists are promising," said Deniel Mero, Co-founder of Elevai Biosciences." Leveraging existing data from ...

EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of ...

EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health ...

--Elevai Labs, Inc., a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. EL ...